Blood test to monitor metastatic colorectal cancer treatment (PROMET)
Part of Cancer, Digestive system clinical trials.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your colorectal cancer has come back after treatment or spread to other parts of the body (metastatic).
- You are able to get radiation therapy along with standard chemotherapy, and possibly an immunotherapy drug called a PD-1 inhibitor.
- Your doctors think you will live at least 6 more months.
- You have not had any other type of cancer in the last 5 years (except certain skin cancers or very early cervical cancer).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks a special blood test (circulating tumor DNA methylation) to help guide follow-up after surgery for non-metastatic colon cancer. It may help find whether additional treatment or closer monitoring is needed based on the test results.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
This study tests whether a special blood test (looking for cancer DNA) can help doctors decide if you need chemotherapy after colorectal cancer surgery. The goal is to avoid unnecessary chemotherapy while making sure patients who need it get treated.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
Hear when a new Metastatic Colorectal Cancer ctDNA Surveillance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.